Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction

IMPORTANCE: Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction (HFrEF). However, clinical inertia often underlies deferred initiation of effective therapies. OBJECTIVE: To examine timing of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Cardiol
Hlavní autoři: Berg, David D., Jhund, Pardeep S., Docherty, Kieran F., Murphy, Sabina A., Verma, Subodh, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sjöstrand, Mikaela, Solomon, Scott D., McMurray, John J. V., Sabatine, Marc S.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2021
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7890451/
https://ncbi.nlm.nih.gov/pubmed/33595593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.7585
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky